+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Intra-Aortic Balloon Pump (IABP) - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2027-2032)

  • PDF Icon

    Report

  • 187 Pages
  • November 2026
  • Region: Global
  • Mordor Intelligence
  • ID: 6294453
The Intra-Aortic balloon pump market size was valued at USD 323.17 million in 2026 and is estimated to grow from USD 341.62 million in 2027 to reach USD 450.95 million by 2032, at a CAGR of 5.71% during the forecast period (2027-2032). This report is Segmented by Product Component (Consoles, Catheters, Introducer Kits), Catheter Type (Fiber-Optic, Ordinary), Indication (AMI-CS, AHF-CS, Mech AMI Complications, HR-PCI, Cardiac Surgery, Bridge To VAD/Transplant, Others), End User (Hospitals, Cardiac Care Centers, Cath Labs, Ascs, Others), and Geography (North America, Europe, Asia-Pacific, MEA, South America). Forecast in Value (USD).

Global Intra-Aortic Balloon Pump (IABP) Market Trends and Insights

Rising High-Risk PCI and Complex Cardiac Procedure Demand

High-risk percutaneous coronary intervention remains a central use case for the Intra-Aortic Balloon Pump market, even as hospitals assess higher-support devices for selected patients. A French study reported that multivessel coronary artery disease increased from 16.4% to 18.4% of cases from 2014 to 2025. IABP systems can be inserted quickly in the catheterization laboratory and do not require a perfusionist. These practical features retain value for hospitals without dedicated mechanical circulatory support teams. In the United States, IABP use during PCI remained between 328 and 356 procedures per 10,000 procedures from 2012 to 2025, which contrasts with declines in the United Kingdom and Canada.

Console Replacement and Installed-Base Service Cycles

The Intra-Aortic Balloon Pump market benefits when older consoles reach end-of-supported-life status, and hospitals must evaluate replacement options. Many installed systems entered service in the early to mid-2010s, which makes serviceability, safety notices, and component availability important procurement considerations. Biomedical engineering teams increasingly compare helium management, transport capability, catheter compatibility, and service history before a capital purchase. Teleflex received FDA 510(k) clearance in April 2025 for the AC3 Range IABP, which was designed for patient support during ambulance and aircraft transport. The system includes a full-size helium tank, dual power inputs, a reinforced extendable handle, and swivel wheels. These features allow procurement teams to assess one console across intensive care, procedure, and transfer settings rather than treating transport as a separate need.

Routine AMI-CS Guideline Downgrade and Competing Support Devices

The 2025 ACC and AHA acute coronary syndrome guideline gives routine IABP use in AMI-related cardiogenic shock a Class 3 no-benefit recommendation. The position reflects findings from IABP-SHOCK II and differs from use in mechanical complications of AMI, where IABP retains clinical relevance. The guideline also affects purchasing decisions at centers that align capital equipment policies with clinical recommendations. Evidence comparing microaxial pumps with IABP may further limit IABP use in selected cardiogenic shock populations. A meta-analysis across 18 studies and 4,500 patients associated Impella with lower 30-day mortality than IABP, while reporting more device-related complications. The Intra-Aortic Balloon Pump market retains support in cardiac surgery, bridge therapy, and moderate-support settings where higher-cost alternatives may not be appropriate.

Other drivers and restraints analyzed in the detailed report include:

  1. Cardiovascular Disease, Aging, and Emerging Cardiac-Care Access
  2. Fiber-Optic Sensor Upgrades and Workflow Digitization
  3. Safety Actions, Staffing, Transport, and Helium Logistics Constraints

Segment Analysis

Intra-aortic balloon catheters commanded 58.40% of the Intra-Aortic Balloon Pump market share in 2027. The category benefits from a recurring purchase pattern because a new catheter is required for each procedure. This model provides a steadier revenue base than console purchases, which are tied to capital budgets and replacement timing. A large installed base of consoles supports continued consumable demand even when hospitals postpone equipment upgrades. Introducer trays and accessory kits represent the smallest product component because they are generally purchased with catheter systems. Their demand follows procedure volume and offers limited standalone purchasing influence. Hospitals evaluate compatibility between catheters and existing consoles before changing suppliers. This creates a practical barrier to switching in established programs. It also supports recurring business for suppliers with a broad installed console base.

IABP consoles are forecast to grow at a 6.30% CAGR through 2032 within the Intra-Aortic Balloon Pump market size. Replacement activity is supported by systems installed in the early 2010s that now face aging components and evolving service requirements. Hospitals do not only compare the purchase price when replacing a console. They also assess portability, battery support, helium management, fiber-optic catheter capability, cybersecurity practices, training needs, and service coverage. Transport demand is making mobility a more visible part of the product decision. Teleflex received FDA clearance for its AC3 Range system in April 2025, which supports use across ground and air transport environments. The device’s dual power inputs and full-size helium tank address continuity of support during transfer. Manufacturers that connect these capabilities to a clear service model can gain attention during replacement cycles.

Ordinary intra-aortic balloon catheters held 71.80% share of the Intra-Aortic Balloon Pump market in 2027. Their position reflects broad compatibility with existing consoles and a lower unit cost for hospitals managing constrained budgets. These catheters remain important in emerging care settings where cost and reliable access are major procurement concerns. The segment also benefits from established clinician familiarity and distributor networks. Standard catheters meet the needs of many procedures where advanced pressure sensing is not required. Their volume base is therefore likely to remain meaningful across large, price-sensitive markets. Compliance with ISO 10993 biocompatibility requirements applies to catheter materials and adds to entry requirements. Product approvals and quality systems also remain important for suppliers seeking broader geographic access. These conditions favor companies with established regulatory capabilities and validated production processes.

Fiber-optic intra-aortic balloon catheters are forecast to grow at a 7.80% CAGR through 2032. Direct pressure measurement at the catheter tip can improve signal quality and timing precision when waveforms are complicated. Sensor profiles between 260 and 550 μm support measurement near the clinical point of use. The feature is particularly relevant in patients with arrhythmias, where conventional signals may be more difficult to interpret. Better dicrotic-notch detection supports a premium clinical case during formulary reviews. It can also increase revenue per console without requiring a proportional increase in procedure volume. In China, high technical requirements for Class III device approvals protect the position of established foreign suppliers. The result is a split pattern where ordinary catheters support broad volume while fiber-optic products contribute more value in higher-acuity settings. Both categories remain necessary across the Intra-Aortic Balloon Pump industry because care capacity and purchasing priorities differ by hospital.

Complete Report Scope:

  • By Product Component
    • Intra-Aortic Balloon Pump Consoles
    • Intra-Aortic Balloon Catheters
    • Introducer Trays and Accessory Kits
  • By Catheter Type
    • Fiber-Optic Intra-Aortic Balloon Catheters
    • Ordinary Intra-Aortic Balloon Catheters
  • By Indication
    • Acute Myocardial Infarction with Cardiogenic Shock
    • Cardiogenic Shock Related to Acute Heart Failure
    • Mechanical Complications of Acute Myocardial Infarction
    • High-Risk Percutaneous Coronary Intervention
    • Cardiac Surgery and Perioperative Hemodynamic Support
    • Bridge to Ventricular Assist Device or Heart Transplantation
    • Other Clinically Defined Indications (Refractory Unstable Angina, Post-Cardiotomy Low Cardiac Output Syndrome, among others)
  • By End User
    • Hospitals
    • Cardiac Care Centers
    • Independent Catheterization Laboratories
    • Ambulatory Surgery Centers
    • Other End Users (Emergency and Interfacility Transport Services, Academic & University Medical Centers, among others)
  • By Geography
    • North America
      • United States
      • Canada
      • Mexico
    • Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • Middle East and Africa
      • GCC
      • South Africa
      • Rest of Middle East and Africa
    • South America
      • Brazil
      • Argentina
      • Rest of South America

Geography Analysis

North America held 42.80% of the Intra-Aortic Balloon Pump market share in 2027. The region has dense catheterization laboratory capacity, an aging console fleet, and established interfacility cardiac transfer networks. More than 50% of U.S. PCI procedures are performed in patients older than 65 years, while people aged 75 years and older account for 30% to 40% of acute coronary syndrome hospitalizations. This patient profile sustains a need for hemodynamic support in complex procedures. The ACC and AHA guideline change may reduce routine use in AMI-related shock. The retained role for mechanical complications and selected perioperative care limits the effect across the full regional base. Teleflex’s AC3 Range clearance addresses a transport need across ambulance, fixed-wing, and rotary-wing care settings.

Asia-Pacific is forecast to grow at a 6.70% CAGR through 2032, the highest regional rate in the Intra-Aortic Balloon Pump market. Limited access to microaxial flow pumps in China and Korea keeps IABP relevant in cardiogenic shock care. In India and South Asia, device cost, training requirements, and referral patterns also shape the choice of mechanical support. Japan’s JROAD-DPC registry captures more than 1.5 million annual cardiovascular hospitalizations, with PCI for AMI exceeding 46,000 cases and a median cardiac patient age of 75 years. Japan, South Korea, Australia, and Singapore can support adoption of premium fiber-optic catheters. China and India contribute procedure volume through broader use of ordinary catheters. The regional pattern supports different product strategies rather than one uniform offering. NMPA Class III approval requirements remain a regulatory influence for manufacturers entering China. These requirements strengthen the importance of quality documentation, local registration capability, and long-term distributor support.

Europe is shaped by established clinical caution regarding routine IABP use in AMI-related cardiogenic shock. Demand is more concentrated in cardiac surgery, perioperative care, bridge therapy, and transport applications. Getinge announced the reinstatement of the Cardiosave CE Mark in August 2025 after an 18-month suspension related to EU MDR compliance. The reinstatement is relevant for hospital replacement planning and European deliveries. Gulf Cooperation Council countries are expanding tertiary cardiac care capacity, which can create new placements in public and specialist hospitals. Other Middle Eastern and African settings face limits from staffing, technical support, and intensive care capacity. South American adoption is concentrated in tertiary centers in Brazil, Chile, and Colombia. These mixed regions require suppliers to pair equipment sales with training, maintenance, and transfer-care support. EU MDR compliance remains an important factor for products supplied into European health systems.



List of Companies Covered in this Report:

  1. Abbott Laboratories
  2. Abiomed
  3. BIOTRONIK SE and Co. KG
  4. Boston Scientific
  5. Cook Group
  6. Fukuda Denshi Co., Ltd.
  7. Getinge
  8. Insightra Medical, Inc.
  9. InterValve, Inc.
  10. Lepu Medical Technology (Beijing) Co., Ltd.
  11. Medtronic
  12. Meril Life Science
  13. MicroPort
  14. Osypka Medical
  15. Senko Medical Instrument Mfg. Co., Ltd.
  16. Teleflex
  17. Terumo
  18. Tokai Medical Products, Inc.
  19. Zeon Medical Inc.
  20. Zoll Medical

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

Table of Contents

1 Introduction
1.1 Study Assumptions & Market Definition
1.2 Scope of the Study
2 Research Methodology3 Executive Summary
4 Market Landscape
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising High-Risk PCI and Complex Cardiac Procedure Demand
4.2.2 Growing Console Replacement and Installed-Base Service Cycles
4.2.3 Cardiovascular Disease and Aging Burden
4.2.4 Access Expansion in Emerging Cardiac-Care Networks
4.2.5 IABP as a Bridge During Transport to Shock Centers
4.2.6 Fiber-Optic Sensor Upgrades and Workflow Digitization
4.3 Market Restraints
4.3.1 Routine AMI-CS Guideline Downgrade and Evidence Uncertainty
4.3.2 Competition from Impella, ECMO, and Other VADs
4.3.3 Recall and Field-Safety Burden on Procurement Decisions
4.3.4 Specialist Staffing, Patient Transport, and Helium Logistics Constraints
4.4 Supply Chain Analysis
4.5 Regulatory Landscape
4.6 Technological Outlook
4.7 Porter's Five Forces Analysis
4.7.1 Threat of New Entrants
4.7.2 Bargaining Power of Suppliers
4.7.3 Bargaining Power of Buyers
4.7.4 Threat of Substitutes
4.7.5 Intensity of Competitive Rivalry
5 Market Size & Growth Forecasts (Value, USD)
5.1 By Product Component
5.1.1 Intra-Aortic Balloon Pump Consoles
5.1.2 Intra-Aortic Balloon Catheters
5.1.3 Introducer Trays and Accessory Kits
5.2 By Catheter Type
5.2.1 Fiber-Optic Intra-Aortic Balloon Catheters
5.2.2 Ordinary Intra-Aortic Balloon Catheters
5.3 By Indication
5.3.1 Acute Myocardial Infarction with Cardiogenic Shock
5.3.2 Cardiogenic Shock Related to Acute Heart Failure
5.3.3 Mechanical Complications of Acute Myocardial Infarction
5.3.4 High-Risk Percutaneous Coronary Intervention
5.3.5 Cardiac Surgery and Perioperative Hemodynamic Support
5.3.6 Bridge to Ventricular Assist Device or Heart Transplantation
5.3.7 Other Clinically Defined Indications (Refractory Unstable Angina, Post-Cardiotomy Low Cardiac Output Syndrome, among others)
5.4 By End User
5.4.1 Hospitals
5.4.2 Cardiac Care Centers
5.4.3 Independent Catheterization Laboratories
5.4.4 Ambulatory Surgery Centers
5.4.5 Other End Users (Emergency and Interfacility Transport Services, Academic & University Medical Centers, among others)
5.5 By Geography
5.5.1 North America
5.5.1.1 United States
5.5.1.2 Canada
5.5.1.3 Mexico
5.5.2 Europe
5.5.2.1 Germany
5.5.2.2 United Kingdom
5.5.2.3 France
5.5.2.4 Italy
5.5.2.5 Spain
5.5.2.6 Rest of Europe
5.5.3 Asia-Pacific
5.5.3.1 China
5.5.3.2 Japan
5.5.3.3 India
5.5.3.4 Australia
5.5.3.5 South Korea
5.5.3.6 Rest of Asia-Pacific
5.5.4 Middle East and Africa
5.5.4.1 GCC
5.5.4.2 South Africa
5.5.4.3 Rest of Middle East and Africa
5.5.5 South America
5.5.5.1 Brazil
5.5.5.2 Argentina
5.5.5.3 Rest of South America
6 Competitive Landscape
6.1 Market Concentration
6.2 Market Share Analysis
6.3 Company Profiles (includes Global Level Overview, Market Level Overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share, Products and Services, Recent Developments)
6.3.1 Abbott Laboratories
6.3.2 Abiomed, Inc.
6.3.3 BIOTRONIK SE and Co. KG
6.3.4 Boston Scientific Corporation
6.3.5 Cook Medical, Inc.
6.3.6 Fukuda Denshi Co., Ltd.
6.3.7 Getinge AB
6.3.8 Insightra Medical, Inc.
6.3.9 InterValve, Inc.
6.3.10 Lepu Medical Technology (Beijing) Co., Ltd.
6.3.11 Medtronic plc
6.3.12 Meril Life Sciences Pvt. Ltd.
6.3.13 MicroPort Scientific Corporation
6.3.14 Osypka Medical GmbH
6.3.15 Senko Medical Instrument Mfg. Co., Ltd.
6.3.16 Teleflex Incorporated
6.3.17 Terumo Corporation
6.3.18 Tokai Medical Products, Inc.
6.3.19 Zeon Medical Inc.
6.3.20 ZOLL Medical Corporation
7 Market Opportunities & Future Outlook
7.1 White-Space and Unmet-Need Assessment

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Abbott Laboratories
  • Abiomed, Inc.
  • BIOTRONIK SE and Co. KG
  • Boston Scientific Corporation
  • Cook Medical, Inc.
  • Fukuda Denshi Co., Ltd.
  • Getinge AB
  • Insightra Medical, Inc.
  • InterValve, Inc.
  • Lepu Medical Technology (Beijing) Co., Ltd.
  • Medtronic plc
  • Meril Life Sciences Pvt. Ltd.
  • MicroPort Scientific Corporation
  • Osypka Medical GmbH
  • Senko Medical Instrument Mfg. Co., Ltd.
  • Teleflex Incorporated
  • Terumo Corporation
  • Tokai Medical Products, Inc.
  • Zeon Medical Inc.
  • ZOLL Medical Corporation